Liver retransplantation is performed in HIV-infected patients, although its outcome is not well known. In an international cohort study (eight countries), 37 (6%; 32 coinfected with hepatitis C virus [HCV] and five with hepatitis B virus [HBV]) of 600 HIV-infected patients who had undergone liver transplant were retransplanted. The main indications for retransplantation were vascular complications (35%), primary graft nonfunction (22%), rejection (19%), and HCV recurrence (13%). Overall, 19 patients (51%) died after retransplantation. Survival at 1, 3, and 5 years was 56%, 51%, and 51%, respectively. Among patients with HCV coinfection, HCV RNA replication status at retransplantation was the only significant prognostic factor. Patients with undetectable versus detectable HCV RNA had a survival probability of 80% versus 39% at 1 year and 80% versus 30% at 3 and 5 years (p = 0.025). Recurrence of hepatitis C was the main cause of death in the latter. Patients with HBV coinfection had survival of 80% at 1, 3, and 5 years after retransplantation. HIV infection was adequately controlled with antiretroviral therapy. In conclusion, liver retransplantation is an acceptable option for HIV-infected patients with HBV or HCV coinfection but undetectable HCV RNA. Retransplantation in patients with HCV replication should be reassessed prospectively in the era of new direct antiviral agents.
Liver Retransplantation in Patients with HIV-1 Infection: An International Multicenter Cohort Study / Aga¼ero, F.; Rimola, A.; Stock, P.; Grossi, P.; Rockstroh, J. K.; Agarwal, K.; Garzoni, C.; Barcan, L. A.; Maltez, F.; Manzardo, C.; Mari, M.; Ragni, M. V.; Anadol, E.; Di Benedetto, F.; Nishida, S.; Gastaca, M.; Mira, J. M.; Pedreira, J. D.; Castro, M. A.; Lapez, S.; Sua¡rez, F.; Vazquez, P.; Blanch, J.; Brunet, M.; Cervera, C.; de Lazzari, E.; Fondevila, C.; Forner, A.; Fuster, J.; Freixa, N.; GarcAa-Valdecasas, J. C.; Gil, A.; Gatell, J. M.; Laguno, M.; Martanez, M.; Mallolas, J.; Monras, M.; Moreno, A.; Murillas, J.; Paredes, D.; Pacopyrightrez, I.; Torres, F.; Tural, C.; Tuset, M.; Antela, A.; Fernandez, J.; Losada, E.; Varo, E.; Lozano, R.; Araiz, J. J.; Barrao, E.; Letona, S.; Luque, P.; Navarro, A.; Sanjoaquan, I.; Serrano, T.; Tejero, E.; Salcedo, M.; BaA+/-ares, R.; Calleja, J.; Berenguer, J.; Cosan, J.; Gutiacopyrightrrez, I.; Lapez, J. C.; Miralles, P.; Ramarez, M.; Rincan, D.; Sanchez, M.; Jimacopyrightnez, M.; de la Cruz, J.; Ferna¡ndez, J. L.; Lozano, J. M.; Santoyo, J.; Rodrigo, J. M.; Sua¡rez, M. A.; Rodraguez, M.; Alonso, M. P.; Asensi, V.; Gonza¡lez, M. L.; GonzA¡lez-Pinto, I.; Rafecas, A.; Carratala¡, J.; Fabregat, J.; Ferna¡ndez, N.; Xiol, X.; Montejo, M.; Bustamante, J.; Ferna¡ndez, J. R.; Montejo, E.; Ortiz de Urbina, J.; Ruiz, P.; Sua¡rez, M. J.; Testillano, M.; Valdivieso, A.; Ventoso, A.; Abradelo, M.; Costa, J. R.; Fundora, Y.; Jimacopyrightnez, S.; Meneu, J. C.; Moreno, E.; Moreno, V.; Olivares, S. P.; Pacopyrightrez, B.; Pulido, F.; Rubio, R.; Blanes, M.; Aguilera, V.; Berenguer, M.; Lapez, J.; Lapez, R.; Prieto, M.; FariA+/-as, M. C.; Arnaiz, A.; Casafont, F.; Echevarria, S.; Fa¡brega, E.; Garcaa, J. D.; Gamez, M.; Gutiacopyrightrrez, J. M.; Peralta, F. G.; Teira, R.; Moreno, S.; Barcena, R.; Del Campo, S.; Fortaºn, J.; Moreno, A. M.; Torre-Cisneros, J.; Barrera, P.; Camacho, A.; Cantisa¡n, S.; Castan, J. J.; de la Mata, M.; Lara, M. R.; Natera, C.; Rivero, A.; Vidal, E.; Castells, L. I.; Charco, R.; Esteban, J. I.; Gavalda¡, J.; Len, O.; Pahissa, A.; Ribera, E.; Vargas, V.; Pons, J. A.; Cordero, E.; Bernal, C.; Cisneros, J. M.; Gamez, M. A.; Pascasio, J. M.; Rodraguez, M. J.; Sayazo, M.; Sousa, J. M.; Sua¡rez, G.; Gonza¡lez, J.; Aznar, E.; Barquilla, E.; Esteban, H.; Krahe, L.; Moyano, B.; de la Rosa, G.; Mahillo, B.; Roland, M.; Ascher, N.; Roberts, J.; Freise, C.; Terrault, N.; Carlson, L.; Beatty, G.; Chin-Hong, P.; Dove, L.; Emond, J.; Lobritto, S.; Neu, N.; Yin, M.; Kumar, A.; Ringe, B.; Jacobson, J.; Sass, D.; Diego, J.; Tzakis, A.; Roth, D.; Schiff, E.; Burke, G.; Jayaweera, D.; Olthoff, K.; Blumberg, E.; Bloom, R.; Reddy, R.; Ragni, M.; Shapiro, R.; De Vera, M. E.; Shakil, O.; Simon, D.; Cohen, S. M.; Dodson, S. F.; Jensik, S.; Saltzberg, S.; Stosor, T.; Green, R.; Baker, T.; Gallon, L.; Scarsi, K.; Hanto, D.; Wong, M.; Curry, M.; Johnson, S.; Pavlakis, M.; Barin, B.; Risaliti, A.; Ancarani, F.; Pinna, A. D.; Morelli, C.; Guaraldi, G.; Tarantino, G.; Baccarani, U.; Tavio, M.; Nanni Costa, A.; Beckebaum, S.; Radecke, K.; Bickel, M.; Sterneck, M.; Zoufaly, A.; Ganten, T.; Stoll, M.; Salzberger, B.; Berg, C.; Kittner, J.; O'Grady, J.; Joshi, D.; Heaton, N.; Smud, A.; Genoud, N.; Cahn, F.; Valledor, A.; Gadano, A.; Barcan, L.; Cusini, A.; Rauch, A.; Furrer, H.; Ma¼ller, N. J.; Khanna, N.; van Delden, C.; Oriol, M.; Manata, M. J.; Correia, F.; Machado, J.; Morbey, A.; Glaria, H.; Veloso, J.; Perdigoto, R.; Pereira, P.; Martins, A.; Barroso, E.. - In: AMERICAN JOURNAL OF TRANSPLANTATION. - ISSN 1600-6135. - 16:2(2016), pp. 679-687. [10.1111/ajt.13461]
Liver Retransplantation in Patients with HIV-1 Infection: An International Multicenter Cohort Study
Di Benedetto F.;Moreno A.;Ragni M.;Pinna A. D.;Morelli C.;Guaraldi G.Membro del Collaboration Group
;Berg C.;
2016
Abstract
Liver retransplantation is performed in HIV-infected patients, although its outcome is not well known. In an international cohort study (eight countries), 37 (6%; 32 coinfected with hepatitis C virus [HCV] and five with hepatitis B virus [HBV]) of 600 HIV-infected patients who had undergone liver transplant were retransplanted. The main indications for retransplantation were vascular complications (35%), primary graft nonfunction (22%), rejection (19%), and HCV recurrence (13%). Overall, 19 patients (51%) died after retransplantation. Survival at 1, 3, and 5 years was 56%, 51%, and 51%, respectively. Among patients with HCV coinfection, HCV RNA replication status at retransplantation was the only significant prognostic factor. Patients with undetectable versus detectable HCV RNA had a survival probability of 80% versus 39% at 1 year and 80% versus 30% at 3 and 5 years (p = 0.025). Recurrence of hepatitis C was the main cause of death in the latter. Patients with HBV coinfection had survival of 80% at 1, 3, and 5 years after retransplantation. HIV infection was adequately controlled with antiretroviral therapy. In conclusion, liver retransplantation is an acceptable option for HIV-infected patients with HBV or HCV coinfection but undetectable HCV RNA. Retransplantation in patients with HCV replication should be reassessed prospectively in the era of new direct antiviral agents.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S1600613522006013-main.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
572.4 kB
Formato
Adobe PDF
|
572.4 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris